Fuda Cancer Hospital, Guangzhou clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 116 studies whose lead sponsor is Fuda Cancer Hospital, Guangzhou. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 9, 2021.
Focus areas
Conditions Fuda Cancer Hospital, Guangzhou leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 116. Browse all 116 →
- Nano Drug Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic CarcinomaNo longer availableNCT02449135
- Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular CarcinomaCompletedNCT04393220Phase 2
- Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor EmboliCompletedNCT02333773Not applicable
- Irreversible Electroporation(IRE) For Unresectable Gallbladder NeoplasmsCompletedNCT02430662Not applicable
- Irreversible Electroporation(IRE) For Unresectable Head and Neck NeoplasmsCompletedNCT02335112Not applicable
- Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases(Close to Nerve)CompletedNCT02430766Not applicable
- Irreversible Electroporation(IRE) For Unresectable Renal TumorsCompletedNCT02335827Not applicable
- Irreversible Electroporation(IRE) For Unresectable Esophageal NeoplasmsCompletedNCT02430701Not applicable
- Percutaneous Irreversible Electroportion for Unresectable Breast CancerCompletedNCT02340858Not applicable
- Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic CancerCompletedNCT02343835Not applicable
- Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver FunctionCompletedNCT02352935Not applicable
- Irreversible Electroporation(IRE) For Uterine Cervical NeoplasmsCompletedNCT02430610Not applicable
- Irreversible Electroporation(IRE) For Unresectable Urinary Bladder NeoplasmsCompletedNCT02430623Not applicable
- Irreversible Electroporation(IRE) For Unresectable Stomach NeoplasmsCompletedNCT02430636Not applicable
- Irreversible Electroporation(IRE) For Unresectable Rectal NeoplasmsCompletedNCT02425059Not applicable
- Percutaneous Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic DomeCompletedNCT02329106Not applicable
- Irreversible Electroporation(IRE) For Unresectable Laryngeal NeoplasmsCompletedNCT02430675Not applicable
- Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral NeoplasmsCompletedNCT02430779Not applicable
- Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPCCompletedNCT03673137Phase 2/3
- Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis NeoplasmsCompletedNCT02430597Not applicable
- Irreversible Electroporation(IRE) For Unresectable Extremities NeoplasmsCompletedNCT02430688Not applicable
- Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function InsufficiencyCompletedNCT02430753Not applicable
- Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the GallbladderCompletedNCT02332551Not applicable
- Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic CancerCompletedNCT02981719Not applicable
- Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic CancerCompletedNCT03180437Phase 1/2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal CancerWithdrawnNCT03524274Phase 2
- Very Small Embryonic-like Stem Cells for OvaryWithdrawnNCT03985462Phase 1/2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver CancerWithdrawnNCT03484962Phase 2
- Very Small Embryonic-like Stem Cells for Knee OsteoarthritisWithdrawnNCT03975101Phase 1/2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric CancerWithdrawnNCT03554395Phase 2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney CancerWithdrawnNCT03540199Phase 2
- Very Small Embryonic-like Stem Cells for Facial Skin AntiagingWithdrawnNCT03976206Phase 1/2
- Very Small Embryonic-like Stem Cells for Erectile DysfunctionWithdrawnNCT03973021Phase 1/2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast CancerWithdrawnNCT03524261Phase 2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung CancerWithdrawnNCT03501056Phase 2
- Hydrogen Gas for Cancer RehabilitationCompletedNCT03818347Not applicable
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic CancerWithdrawnNCT03509298Phase 2
- Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid TumorsCompletedNCT02857920Phase 1/2
- CD19-targeting CAR T Cells for B Cell LymphomaWithdrawnNCT02547948Phase 1/2
- CAR-T Cell Immunotherapy for GD2 Positive Glioma PatientsWithdrawnNCT04406610Phase 1/2
- CAR-T Cell Immunotherapy for HCC Targeting GPC3WithdrawnNCT02723942Phase 1/2
- CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma PatientsWithdrawnNCT02575261Phase 1/2
- Chimeric Antigen Receptor-Modified T Cells for Breast CancerWithdrawnNCT02547961Phase 1/2
- CAR-T Cell Immunotherapy for GD2 Positive Glioma PatientsWithdrawnNCT03252171Phase 1/2
- Safety and Efficiency of γδ T Cell Against Lung CancerCompletedNCT03183232Phase 1/2
- Safety and Efficiency of γδ T Cell Against Liver CancerCompletedNCT03183219Phase 1/2
- Safety and Efficiency of γδ T Cell Against Breast CancerCompletedNCT03183206Phase 1/2
- Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid TumorsCompletedNCT02843204Phase 1/2
- Irreversible Electroporation(IRE) For Unresectable Prostatic NeoplasmsWithdrawnNCT02430649Not applicable
- Cryotherapy Combine Icotinib for Advanced NSCLC TreatmentCompletedNCT02744664Phase 4